Q32 Bio (QTTB) Return on Capital Employed (2018 - 2026)
Q32 Bio's quarterly Return on Capital Employed came in at 41.13% in Q1 2026, up 13039.0% year-on-year from N/an in Q1 2025, and up 17.84% quarter-over-quarter from 34.9% in Q4 2025.
Q32 Bio has reported Return on Capital Employed for 9 years, with the latest figure at 41.13% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 13039.0% year-over-year to 41.13%; the trailing twelve-month figure through Mar 2026 stood at 41.13% (up 13039.0% YoY), and the FY2025 full-year result was 25.72%, up 14991.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 41.13%, up from 34.9% in the prior quarter.
- The five-year high for Return on Capital Employed was 58.3% in Q3 2023, with the low at 89.65% in Q2 2025.
- Average Return on Capital Employed over 5 years is 29.83%, with a median of 23.54% recorded in 2022.
- Year-over-year, Return on Capital Employed plunged 13569 bps in 2024 and surged 13039 bps in 2026.
- Tracing QTTB's Return on Capital Employed over 5 years: stood at 0.4% in 2022, then tumbled by 14931 bps to 60.74% in 2023, then tumbled by 33 bps to 80.64% in 2024, then surged by 143 bps to 34.9% in 2025, then increased by 18 bps to 41.13% in 2026.
- The last three Return on Capital Employed figures came in at 41.13% (Q1 2026), 34.9% (Q4 2025), and 85.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 41.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.13% |
| Dec 31, 2025 | 34.90% |
| Sep 30, 2025 | -85.57% |
| Jun 30, 2025 | -89.65% |
| Mar 31, 2025 | -89.26% |
| Dec 31, 2024 | -80.64% |
| Sep 30, 2024 | -77.39% |
| Jun 30, 2024 | -54.82% |
| Mar 31, 2024 | -83.49% |
| Dec 31, 2023 | -60.74% |
| Sep 30, 2023 | 58.30% |
| Jun 30, 2023 | 31.35% |
| Mar 31, 2023 | 15.07% |
| Dec 31, 2022 | -0.40% |
| Sep 30, 2022 | -22.78% |
| Jun 30, 2022 | -19.63% |
| Mar 31, 2022 | -23.54% |
| Dec 31, 2021 | -9.86% |
| Sep 30, 2021 | -40.73% |
| Jun 30, 2021 | -39.48% |
| Mar 31, 2021 | -41.00% |
| Dec 31, 2020 | -58.31% |
| Sep 30, 2020 | -55.73% |
| Jun 30, 2020 | -50.81% |
| Mar 31, 2020 | -42.98% |
| Dec 31, 2019 | -36.49% |
| Sep 30, 2019 | -33.70% |
| Jun 30, 2019 | -32.73% |
| Mar 31, 2019 | -32.55% |
| Dec 31, 2018 | -24.84% |
| Sep 30, 2018 | -20.74% |
| Jun 30, 2018 | -22.80% |
| Mar 31, 2018 | -28.79% |